Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises

Cellular and Molecular Life Sciences

Volumn 54, Issue 12, 1998, Pages 1291-1298

  Mueller, H ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

Cancer therapy; Cytokines; Endotoxin; Gene therapy; Turner necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CHILL; CLINICAL TRIAL; DRUG TOXICITY; FATIGUE; FEVER; GENE THERAPY; HEADACHE; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEIOTROPY; REVIEW; RIGOR; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FORECASTING; GENE THERAPY; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0032415437     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050255     Document Type: Review

References (117)

1. Carswell E. A., Old L. J., Kassel R. L., Green S., Fiore N. and Williamson B. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670
2. Fiers W. (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 285: 199-212
3. Vilcek J. and Lee T. H. (1991) Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266: 7313-7316
4. Jäätelä M. (1991) Biology of disease: biologic activities and mechanisms of action of tumor necrosis factor-alpha. Lab. Invest. 64: 724-742
5. Laster S. M., Wood J. G. and Gooding L. R. (1988) Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J. Immunol. 141: 2629-2634
6. Cseh K. and Beutler B. (1989) Alternative cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein. J. Biol. Chem. 264: 16256-16260
7. Shirai T., Yamaguchi H., Ito H., Todd C. W. and Wallace R. B. (1985) Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 313: 803-806
8. Aggarwal B. B., Kohr W. J., Hass P. E., Moffat B., Spencer S. A., Henzel W. J. et al. (1985) Human tumor necrosis factor. Production, purification and characterization. J. Biol. Chem. 260: 2345-2354
9. Sreekrishna K., Nelles L., Potenz R., Cruze J., Mazzaferro P., Fish W. et al. (1989) High-level expression, purification and characterization of recombinant human tumor necrosis factor synthesized in the methylotrophic yeast Pichia pastoris. Biochemistry 28: 4117-4125
10. Eck M. J. and Sprang S. R. (1989) The structure of tumor necrosis factor-alpha at 2.6 Å resolution. Implications for receptor binding. J. Biol. Chem. 264: 17595-17605
11. Rothe J., Gehr G., Loetscher H. and Lesslauer W. (1992) Tumor necrosis factor receptors structure and function. Immunol. Res. 11: 16-19
12. Mueller H., Flury N., Liu R., Scheidegger S., Kueng W. and Eppenberger U. (1996) Tumor necrosis factor and interferon are selectively cytostatic for hormone-dependent and hormone-independent human breast cancer cells. Eur. J. Cancer 32A: 2312-2318
13. Beyaert R. and Fiers W. (1994) Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett. 340: 9-16
14. Naismith J. H. and Sprang S. R. (1998) Modularity in the TNF-receptor family. Trends Biochem. Sci. 23: 74-79
15. Beutler B. and van Huffel C. (1994) Unraveling function in the TNF ligand and receptor families. Science 264: 667-668
16. Loetscher H., Pan Y.-C. E., Lahm H.-W., Gentz R., Brockhaus M., Tabuchi H. et al. (1990) Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell 61: 351-359
17. Schall T. J., Lewis M., Koller K. J., Lee A., Rice G. C., Wong G. H. et al. (1990) Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61: 361-370
18. Nophar Y., Kemper O., Brakebusch C., Englemann H., Zwang R., Aderka D. et al. (1990) Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R. cloned using ammo acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 9: 3269-3278
19. Himmler A., Maurer-Fogy I., Kronke M., Scheurich P., Pfizenmaier K., Lantz M. et al. (1990) Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein. DNA Cell Biol. 9: 705-715
20. Kohno T., Brewer M. T., Baker S. L., Schwartz P. E., King M. W., Hale K. K. et al. (1990) A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. USA 87: 8331-8335
21. Smith C. A., Davis T., Anderson D., Solam L., Beckmann M. P., Jerzy R. et al. (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019-1023
22. Gray P. W., Barrett K., Chantry D., Turner M. and Feldmann M. (1990) Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein. Proc. Natl. Acad. Sci. USA 87: 7380-7384
23. Kuhnert P., Kemper O. and Wallach D. (1994) Cloning, sequencing and partial functional characterization of the 5′ region of the human p75 tumor necrosis factor receptor-encoding gene (TNF-R). Gene 150: 381-386
24. Grell M., Wajant H., Zimmermann G. and Scheurich P. (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA 95: 570-575
25. Wiegmann K., Schutze S., Kampen E., Himmler A., Machleidt T. and Kronke M. (1992) Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 267: 17997-18001
26. Tartaglia L. A., Rothe M., Hu Y.-F. and Goeddel D. V. (1993) Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73: 213-216
27. Kolesinck R. and Golde D. W. (1994) The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signalling. Cell 77: 325-328
28. Schutze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K. and Kronke M. (1992) TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell 71: 765-776
29. Imamura K., Spriggs D. and Kufe D. (1987) Expression of tumor necrosis factor receptors on human monocytes and internalization of receptor bound ligand. J. Immunol. 139: 2989-2992
30. Tsujimoto M., Yip Y. K. and Vilcek J. (1985) Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. Proc. Natl. Acad. Sci. USA 82: 7626-7630
31. Johnson S. E. and Baglioni C. (1988) Tumor necrosis factor receptors and cytocidal activity are down-regulated by activators of protein kinase C. J. Biol. Chem. 263: 5686-5692
32. Unglaub R., Maxeiner B., Thoma B., Pfizenmaier K. and Scheurich P. (1987) Downregulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators. J. Exp. Med. 166: 1788-1797
33. Aggarwal B. B. and Eessalu T. E. (1987) Effect of phorbol esters on down-regulation and redistribution of cell surface receptors for tumor necrosis factor-alpha. J. Biol. Chem. 262: 16450-16455
34. Watanabe N., Kuriyama H., Sone H., Neda H., Yamauchi N., Maeda M. et al. (1988) Continuous internalization of tumor necrosis factor receptors in a human myosarcoma cell line. J. Biol. Chem. 263: 10262-10266
35. Vuk-Pavlovic S. and Kovach J. S. (1989) Recycling of tumor necrosis factor-alpha receptor in MCF-7 cells. FASEB J. 3: 2633-2640
36. Bajzer Z., Myers A. C. and Vuk-Pavlovic S. (1989) Binding, internalization and intracellular processing of proteins interacting with recycling receptors. A kinetic analysis. J. Biol. Chem. 264: 13623-13631
37. Higuchi M. and Aggarwal B. B. (1994) TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J. Immunol. 152: 3550-3558
38. Porteu F. and Hieblot C. (1994) Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J. Biol. Chem. 269: 2834-2840
39. Zhang L. and Aggarwal B. B. (1994) Role of sulfhydryl groups in induction of cell surface down-modulation and shedding of extracellular domain of human TNF receptors in human histiocytic lymphoma U937 cells. J. Immunol. 153: 3745-3754
40. Terlizzese M., Simoni P. and Antonetti F. (1996) In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP 1) against TNF-alpha and TNF-beta. J. Interferon Cytokine Res. 16: 1047-1053
41. Gatanaga T., Hwang C. D., Kohr W., Cappuccini F., Lucci J. A. D., Jeffes E. W. et al. (1990) Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci. USA 87: 8781-8784
42. Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M. et al. (1993) Human TNF mutants with selective activity on the p55 receptor. Nature 361: 266-269
43. Barbara J. A., Smith W. B., Gamble J. R., Van Ostade X., Vandenabecle P., Tavernier J. et al. (1994) Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. EMBO J. 13: 843-850
44. Espevik T., Brockhaus M., Loetscher H., Nonstad U. and Shalaby R. (1990) Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor. J. Exp. Med. 171: 415-426
45. Thoma B., Grell M., Pfizenmaier K. and Scheurich P. (1990) Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J. Exp. Med. 172: 1019-1023
46. Brakebusch C., Nophar Y., Kemper O., Engelmann H. and Wallach D. (1992) Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 11: 943-950
47. Tartaglia L. A. and Goeddel D. V. (1992) Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J. Biol. Chem. 267: 4304-4307
48. Tartaglia L. A., Weber R. F., Figari I. S., Reynolds C. Palladino M. A. Jr. and Goeddel D. V. (1991) The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 88: 9292-9296
49. Bigda J., Beletsky I., Brakebusch C., Varfolomeev Y., Engelmann H., Holtmann H. et al. (1994) Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J. Exp. Med. 180: 445-460
50. Reid T., Louie P. and Heller R. A. (1994) Mechanisms of tumor necrosis factor cytotoxicity and the cytotoxic signals transduced by the p75-tumor necrosis factor receptor. Circ. Shock 44: 84-90
51. Vandenabeele P., Goossens V., Beyaert R., Declercq W., Grooten J., Vanhaesebroeck B. et al. (1994) Functional requirement of the two TNF receptors for induction of apoptosis in PC60 cells and the role of mitochondria in TNF-induced cytotoxicity. Circ. Shock 44: 196-200
52. Vandenabeele P., Declercq W., Vanhaesebroeck B., Grooten J. and Fiers W. (1995) Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J. Immunol. 154: 2904-2913
53. Declercq W., Denecker G., Fiers W. and Vandenabeele P. (1998) Cooperation of both TNF receptors in inducing apoptosis: involvement of the TNF receptor-associated factor binding domain of the TNF receptor 75. J. Immunol. 161: 390-399
54. Shear M. J., Turner F. C. and Perrault A. (1943) Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J. Natl. Cancer Inst. 4: 81-97
55. Logan T. F., Gooding W. E., Whiteside T. L., Ernstoff M. S., Kaplan S. S., Miketic L. et al. (1997) Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients. J. Immunother. 20: 387-398
56. Vosika G. J., Barr C. and Gilbertson D. (1984) Phase-I study of intravenous modified lipid A. Cancer Immunol. Immunother. 18: 107-112
57. Engelhardt R., Mackensen A. and Galanos C. (1991) Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 51: 2524-2530
58. Otto F., Schmid P., Mackensen A., Wehr U., Seiz A., Braun M. et al. (1996) Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur. J. Cancer 32A: 1712-1718
59. Niida H., Takeuchi S., Tanaka R. and Minakawa T. (1995) Angiogenesis in microvascular endothelial cells induced by glioma cells and inhibited by tumor necrosis factor in vitro. Neurol. Med. Chir. 35: 209-214
60. Montrucchio G., Lupia E., Battaglia E., Passerini G., Bussolino F., Emanuelli G. et al. (1994) Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J. Exp. Med. 180: 377-382
61. Billington D. C. (1991) Angiogenesis and its inhibition: potential new therapies in oncology and non-neoplastic diseases. Drug Des. Discov. 8: 3-35
62. Sato N., Fukuda K., Nariuchi H. and Sagara N. (1987) Tumor necrosis factor inhibiting angiogenesis in vitro. J. Natl. Cancer Inst. 79: 1383-1391
63. Schweigerer L., Malerstein B. and Gospodarowicz D. (1987) Tumor necrosis factor inhibits the proliferation of cultured capillary endothelial cells. Biochem. Biophys. Res. Commun. 143: 997-1004
64. Koolwijk P., van Erck M. G., de Vree W. J., Vermeer M. A., Weich H. A., Hanemaaijer R. et al. (1996) Cooperative effect of TNFalpha, bFGF and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. 132: 1177-1188
65. Patterson C., Perrella M. A., Endege W. O., Yoshizumi M., Lee M. E. and Haber E. (1996) Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Invest. 98: 490-496
66. Fajardo L. F., Kwan H. H., Kowalski J., Prionas S. D. and Allison A. C. (1992) Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 140: 539-544
67. Sunderkotter C., Goebeler M., Schulze-Osthoff K., Bhardwaj R. and Sorg C. (1991) Macrophage-derived angiogenesis factors. Pharmacol. Ther. 51: 195-216
68. Leibovich S. J., Polverini P. J., Shepard H. M., Wiseman D. M., Shively V. and Nuseir N. (1987) Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329: 630-632
69. Kirstein M. and Baglioni C. (1988) Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation of c-myc messenger RNA. J. Cell Physiol. 134: 479-484
70. Hoang T., Levy B., Onetto N., Haman A. and Rodriguez-Cimadevilla J. C. (1989) Tumor necrosis factor alpha stimulates the growth of the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte macrophage colony-stimulating factor. J. Exp. Med. 170: 15-26
71. Miura K., Teramura M., Hoshino S., Mizoguchi H. and Sato T. (1992) Stimulatory effect of tumor necrosis factor-alpha on the growth of CMK, a human megakaryoblastic leukemia cell line. Leuk. Res. 16: 281-285
72. Wu S., Boyer C. M., Whitaker R. S., Berchuck A., Wiener J. R., Weinberg J. B. et al. (1993) Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 53: 1939-1944
73. Woodworth C. D., McMullin E., Iglesias M. and Plowman G. D. (1995) Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc. Natl. Acad. Sci. USA 92: 2840-2844
74. Flury N., Eppenberger U. and Mueller H. (1997) Tumor necrosis factor alpha modulates mitogen-activated protein kinase activity of epidermal growth factor-stimulated MCF-7 breast cancer cells. Eur. J. Biochem. 249: 421-426
75. Lu G., Beuerman R. W., Zhao S., Sun G., Nguyen D. H., Ma S. et al. (1997) Tumor necrosis factor-alpha and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts. Neurochem. Int. 30: 401-410
76. Brach M. A., Gruss H. J., Sott C. and Hermann F. (1993) The mitogenic response to tumor necrosis factor alpha requires c-Jun/AP-1. Mol. Cell. Biol. 13: 4284-4290
77. Malik S. T. (1992) Tumour necrosis factor: roles in cancer pathophysiology. Semin. Cancer Biol. 3: 27-33
78. Sugerman B. J., Aggerwal B. B. and Hess P. E. (1985) Recombinant human tumor necrosis factor alpha: effects on proliferation of normal and transformed cells in vivo. Science 230: 943-945
79. Fransen L., Van der Heyden J., Ruysschart R. and Fiers W. (1986) Recombinant tumor necosis factor: its effect and its synergism with interferon gamma on a variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 22: 419-426
80. Dealtry G. B., Naylor M. S., Fiers W. and Balkwill F. R. (1987) the effect of recombinant human tumor necrosis factor on growth and macromolecular synthesis of human epithelial cells. Exp. Cell Res. 170: 428-438
81. Spriggs D., Imamura K., Rodriguez C., Horiguchi C. and Kufwe D. W. (1987) Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Natl. Acad. Sci. USA 84: 6563-6566
82. Ruggiero V., Latham K. and Baglioni C. (1987) Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J. Immunol. 138: 1711-1717
83. Zamkoff K. W., Newman N. B., Rudolph A. R., Young J. and Poiesz B. J. (1989) A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. J. Biol. Response Mod. 8: 539-552
84. Furman W. L., Strother D., McClain K., Bell B., Leventhal B. and Pratt C. B. (1993) Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study. J. Clin. Oncol. 11: 2205-2210
85. Feinberg B., Kurzrock R., Talpaz M., Blick M., Saks S. and Gutterman J. U. (1988) A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J. Clin. Oncol. 6: 1328-1334
86. Creaven P. J., Plager J. E., Dupere S., Huben R. P., Takita H., Mittelman A. et al. (1987) Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 20: 137-144
87. Gamm H., Lindemann A., Mertelsmann R. and Herrmann F. (1991) Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur. J. Cancer 27: 856-863
88. Blick M., Sherwin S. A., Rosenblum M. and Gutterman J. (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 47: 2986-2989
89. Schiller J. H., Storer B. E., Witt P. L., Alberti D., Tombes M. B., Arzoomanian R. et al. (1991 ) Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res. 51: 1651-1658
90. Aulitzky W. E., Tilg H., Gastl G., Mull R., Flener R., Vogel W. et al. (1991) Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. Eur. J. Cancer 27: 462-467
91. Demetri G. D., Spriggs D. R., Sherman M. L., Arthur K. A., Imamura K. and Kufe D. W. (1989) A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J. Clin. Oncol. 7: 1545-1553
92. Eskander E. D., Harvey H. A., Givant E. and Lipton A. (1997) Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2. Am. J. Clin. Oncol. 20: 511-514
93. Aggarwal B. B., Eessalu T. E. and Hass P. E. (1985) Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon. Nature 318: 665-667
94. Naomoto Y., Tanaka N. and Orita K. (1989) Antitumor effect of natural human tumor necrosis factor-alpha and natural human interferon-alpha in combination against human cancer transplanted into nude mice. Acta Med. Okayama 43: 211-221
95. Lenk H., Tanneberger S., Muller U., Ebert J. and Shiga T. (1989) Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 24: 391-392
96. Kemeny N., Childs B., Larchian W., Rosado K. and Kelsen D. (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66: 659-663
97. Whitehead R. P., Fleming T., Macdonald J. S., Goodman P. J., Neefe J., Braun T. J. et al. (1990) A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. J. Biol. Response Mod. 9: 588-591
98. Brown T. D., Goodman P., Fleming T., Macdonald J. S., Hersh E. M. and Braun T. J. (1991) A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J. Immunother. 10: 376-378
99. Budd G. T., Green S., Baker L. H., Hersh E. P., Weick J. K. and Osborne C. K. (1991) A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 68: 1694-1695
100. Helson L. (1992) A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 69: 2866
101. Feldman E. R., Creagan E. T., Schaid D. J. and Ahmann D. L. (1992) Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am. J. Clin. Oncol. 15: 256-259
102. Fraker D. L. and Alexander H. R. (1994) Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. Important Adv. Oncol. 179-192
103. Lienard D., Eggermont A. M., Schraffordt Koops H., Kroon B. B., Rosenkaimer F., Autier P. et al. (1994) Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res. 4 (Suppl 1): 21-26
104. Fraker D. L. and Alexander H. R. (1994) The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res. 4 (Suppl 1): 27-29
105. Lejeune F., Lienard D., Eggermont A., Schraffordt Koops H., Kroon B., Gerain J. et al. (1994) Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. Circ. Shock 43: 191-197
106. Lejeune F., Lienard D., Eggermont A., Schraffordt Koops H., Rosenkaimer F., Gerain J. et al. (1995) Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. J. Infus. Chemother. 5: 73-81
107. Walther M. M., Jennings S. B., Choyke P. L., Andrich M., Hurley K., Linehan W. M. et al. (1996) Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J. Urol. 14: S2-7
108. Borel Rinkes I. H., de Vries M. R., Jonker A. M., Swaak T. J., Hack C. E., Nooyen P. T. et al. (1997) Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. Br. J. Cancer 75: 1447-1453
109. Vahrmeijer A. L., Van Der Eb M. M., Van Dierendonck J. H., Kuppen P. J. and Van De Velde C. J. (1998) Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases? Semin. Surg. Oncol. 14: 262-268
110. Alexander H. R., Bartlett D. L., Libutti S. K., Fraker D. L., Moser T. and Rosenberg S. A. (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J. Clin. Oncol. 16: 1479-1489
111. Eggermont A. M. (1996) The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and pre-clinical perfusion models. Gan To Kagaku Ryoho 23: 1357-1370
112. Hohenberger P. and Kettelhack C. (1998) Clinical management and current research in isolated limb perfusion for sarcoma and melanoma. Oncology 55: 89-102
113. Sato Y., Koshita Y., Hirayama M., Matuyama T., Wakimoto H., Hamada H. et al. (1996) Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients. Hum. Gene Ther. 7: 1895-1905
114. Fushimi K., Torigoe K., Yamauchi H., Furusako S., Kurimoto M. and Namba M. (1998) Establishment of a human fibroblast cell line producing tumor necrosis factor alpha (KMST-6 TNF) and growth inhibitory effects of its conditioned medium on malignant cells in culture. In Vitro Cell Dev. Biol. Anim. 34: 463-467
115. Staba M. J., Mauceri H. J., Kufe D. W., Hallahan D. E. and Weichselbaum R. R. (1998) Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther. 5: 293-300
116. Sato T., Yamauchi N., Sasaki H., Takahashi M., Okamoto T., Sakamaki S. et al. (1998) An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res. 58: 1677-1683
117. Marr R. A., Hitt M., Muller W. J., Gauldie J. and Graham F. L. (1998) Tumour therapy in mice using adenovirus vectors expressing human TNFx. Int. J. Oncol. 12: 509-515